AstraZeneca Pharma India Limited has received a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Integrated Registry Management Services Private Limited, validates adherence to regulations regarding the dematerialization of securities for the period from September 1, 2025, to September 30, 2025.
Certificate of Compliance
AstraZeneca Pharma India Limited confirms it has received a certificate from Integrated Registry Management Services Private Limited, the Registrar and Transfer Agent (RTA), ensuring compliance with stipulated regulations.
Details of Compliance
The certificate, dated October 7, 2025, confirms adherence to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period covering September 1, 2025 to September 30, 2025. This regulation pertains to activities related to the dematerialization of securities.
Key Compliance Actions
The compliance includes the following key actions:
- The securities comprised in the certificate(s) Dematerialized, are listed on the stock exchange or exchanges where the earlier issued securities are listed.
- Mutilated and canceled the certificate of security forwarded by the participants.
- Substituted the name of the depository as the registered owner in our records.
Source: BSE
